Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).

Date publication

décembre 2020

Journal

Brain and behavior

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas , Pr DE SEZE Jérôme

Tous les auteurs :
Collongues N, Kuhle J, Tsagkas C, Lamy J, Meyer N, Barro C, Parmar K, Amann M, Wuerfel J, Kappos L, Moreau T, de Seze J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33314801

Résumé

High-dose pharmaceutical-grade biotin (MD1003) has positive effects on disability in progressive multiple sclerosis (PMS), but its mechanism of action remains unclear. The objective of our study was to quantify the effect of MD1003 in patients with PMS, using clinical response, plasma neurofilament light chain (pNfL) levels, and brain (BV) or cervical spinal cord volume (CSCV).

Mots clés

MD1003, brain volume, multiple sclerosis, neurofilament light chain, progressive form, spinal cord volume

Référence

Brain Behav. 2020 Dec 13;:e01998